CN111542328A - 用于治疗癌症的包含α-聚谷氨酸-锌的组合物 - Google Patents

用于治疗癌症的包含α-聚谷氨酸-锌的组合物 Download PDF

Info

Publication number
CN111542328A
CN111542328A CN201880084765.4A CN201880084765A CN111542328A CN 111542328 A CN111542328 A CN 111542328A CN 201880084765 A CN201880084765 A CN 201880084765A CN 111542328 A CN111542328 A CN 111542328A
Authority
CN
China
Prior art keywords
zinc
dosage form
alpha
polyglutamic acid
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880084765.4A
Other languages
English (en)
Chinese (zh)
Inventor
郑镇赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhai Lunix Private Ltd
Original Assignee
Xylonix IP Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylonix IP Holdings Pte Ltd filed Critical Xylonix IP Holdings Pte Ltd
Publication of CN111542328A publication Critical patent/CN111542328A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880084765.4A 2017-10-30 2018-10-29 用于治疗癌症的包含α-聚谷氨酸-锌的组合物 Pending CN111542328A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201708886R 2017-10-30
SG10201708886RA SG10201708886RA (en) 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
PCT/SG2018/050544 WO2019088919A1 (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer

Publications (1)

Publication Number Publication Date
CN111542328A true CN111542328A (zh) 2020-08-14

Family

ID=64184154

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880084765.4A Pending CN111542328A (zh) 2017-10-30 2018-10-29 用于治疗癌症的包含α-聚谷氨酸-锌的组合物

Country Status (7)

Country Link
US (1) US20200254013A1 (enExample)
EP (1) EP3703708A1 (enExample)
JP (1) JP7352541B2 (enExample)
KR (1) KR102725852B1 (enExample)
CN (1) CN111542328A (enExample)
SG (2) SG10201708886RA (enExample)
WO (1) WO2019088919A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CN117377497A (zh) 2021-03-18 2024-01-09 翟伦尼克斯私人有限公司 药物聚合物缀合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080253969A1 (en) * 2007-04-10 2008-10-16 Nitto Denko Corporation Multi-functional polyglutamate drug carriers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
AU2291001A (en) * 1999-12-23 2001-07-03 Emory University Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20020061599A1 (en) * 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
WO2003061598A2 (en) * 2002-01-25 2003-07-31 The University Of Georgia Research Foundation, Inc. Solenopsin a, b and analogs as novel angiogenesis inhibitors
EP1890537B1 (en) * 2005-06-07 2012-08-08 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
JPWO2007043606A1 (ja) * 2005-10-12 2009-04-16 株式会社ジェノラックＢｌ アニオン性ポリアミノ酸／金属複合体からなる抗糖尿病薬剤
CN101795677B (zh) * 2007-05-09 2012-11-14 沙路特里亚制药有限责任公司 用于治疗炎性病症的螺环化合物
WO2008141110A2 (en) 2007-05-09 2008-11-20 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
US20110117210A1 (en) * 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
US9132098B2 (en) 2013-03-28 2015-09-15 Bbs Nanotechnology Ltd. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
CN105143242A (zh) 2013-04-26 2015-12-09 日东电工株式会社 大规模制备聚(谷氨酰基-谷氨酸盐)偶联物的方法
SG10201609131YA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080253969A1 (en) * 2007-04-10 2008-10-16 Nitto Denko Corporation Multi-functional polyglutamate drug carriers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KARMAKER SUBARNA等: ""A Zinc(II)/Poly(g-glutamic acid) Complex as an Oral Therapeutic for the Treatment of Type-2 Diabetic KKAy Mice"", 《MICROMOLECULAR BIOSCIENCE》 *
KAZUHIRO IGUCHI等: ""Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction"", 《EUR. J. BIOCHEM.》 *
PERKINS等: ""Zn 2+ binding to poly-C-glutamic acid and human serum albumin"", 《BIOCHIMICA ET BIOPHYSICA ACTA(BBA) –GENERAL SUBJECTS，ELSEVIER，AMSTERDAM，NL》 *

Also Published As

Publication number Publication date
KR20200080271A (ko) 2020-07-06
KR102725852B1 (ko) 2024-11-05
EP3703708A1 (en) 2020-09-09
SG10201708886RA (en) 2019-05-30
WO2019088919A1 (en) 2019-05-09
US20200254013A1 (en) 2020-08-13
JP7352541B2 (ja) 2023-09-28
SG11202003967PA (en) 2020-05-28
JP2021501143A (ja) 2021-01-14

Similar Documents

Publication Publication Date Title
JP7466822B2 (ja) 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法
Van der Merwe et al. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs
US11471422B2 (en) Stealth, targeted nanoparticles (STN) for oral drug delivery
EP2900230B1 (en) Compounds for the treatment of obesity and methods of use thereof
CN110087632A (zh) 乳酸钙组合物和使用方法
US10905661B2 (en) Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
JP2021509661A (ja) コレステロール、グルコースおよびマイクロバイオームを制御するための組成物および方法
JP2019518758A (ja) 粘膜付着性材料によって被覆された個々のコア単位を有するコアと腸溶性コアコーティングを備えた多単位投薬形態
JP2025148479A (ja) ガンマ－ポリグルタミン酸および亜鉛組成物
JP7352541B2 (ja) がんを処置するためのアルファ－ポリグルタミン酸－亜鉛を含む組成物
HK40035636A (en) Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
KR100882873B1 (ko) 카테킨 함유 리포솜을 포집하는 펙틴 전달체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40035636

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20240328

Address after: Montbatten Road, Singapore

Applicant after: Zhai Lunix Private Ltd.

Country or region after: Singapore

Address before: Shinka ha

Applicant before: Xylonix IP Holdings Pte. Ltd.

Country or region before: Singapore

TA01 Transfer of patent application right